UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Interleukin-6 and prostate cancer: Current developments and unsolved questions

Molecular and cellular endocrinology, 2018-02, Vol.462 (Pt A), p.25-30

2018

Volltextzugriff (PDF)

Interleukin-6: A multifunctional targetable cytokine in human prostate cancer

Molecular and cellular endocrinology, 2012-09, Vol.360 (1-2), p.52-58

2012

Volltextzugriff (PDF)

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

Clinical cancer research, 2018-02, Vol.24 (4), p.927-938

2018

Volltextzugriff (PDF)

The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer

Molecular oncology, 2017-03, Vol.11 (3), p.251-265

2017

Volltextzugriff (PDF)

Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205

The American journal of pathology, 2012-12, Vol.181 (6), p.2188-2201

2012

Volltextzugriff (PDF)

Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells

Oncotarget, 2016-09, Vol.7 (38), p.61890-61904

2016

Volltextzugriff (PDF)

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer

Molecular endocrinology (Baltimore, Md.), 2015-07, Vol.29 (7), p.1037-1054

2015

Volltextzugriff (PDF)

New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium

Journal of translational medicine, 2024-01, Vol.22 (1), p.71-8, Article 71

2024

Volltextzugriff (PDF)

Androgen Receptor–Interacting Proteins in Prostate Cancer Development and Therapy Resistance

The American journal of pathology, 2024-03, Vol.194 (3), p.324-334

2024

Volltextzugriff (PDF)

Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium

Journal of experimental & clinical cancer research, 2024-07, Vol.43 (1), p.1-14, Article 194

2024

Volltextzugriff (PDF)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide

Oncotarget, 2016-09, Vol.7 (37), p.59781-59794

2016

Volltextzugriff (PDF)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells

Frontiers in oncology, 2022-02, Vol.12, p.789284

2022

Volltextzugriff (PDF)

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Endocrine-related cancer, 2016-01, Vol.23 (1), p.35-45

2016

Volltextzugriff (PDF)

Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer

Cells (Basel, Switzerland), 2022-12, Vol.11 (24), p.4026

2022

Volltextzugriff (PDF)

Antidiabetic drugs influence molecular mechanisms in prostate cancer

Cancer biology & therapy, 2018-12, Vol.19 (12), p.1153-1161

2018

Volltextzugriff (PDF)

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

Molecular oncology, 2020-10, Vol.14 (10), p.2487-2503

2020

Volltextzugriff (PDF)

Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo

Endocrine-related cancer, 2010-06, Vol.17 (2), p.481-493

2010

Volltextzugriff (PDF)

Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (18), p.7375-7384

2009

Volltextzugriff (PDF)

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells

Oncotarget, 2014-12, Vol.5 (23), p.12043-12056

2014

Volltextzugriff (PDF)

Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases

The American journal of pathology, 2009-05, Vol.174 (5), p.1921-1930

2009

Volltextzugriff (PDF)

Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo

PloS one, 2015-02, Vol.10 (2), p.e0117806

2015

Volltextzugriff (PDF)

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling

Endocrine-related cancer, 2010-06, Vol.17 (2), p.525-538

2010

Volltextzugriff (PDF)

Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion

Endocrine-related cancer, 2007-12, Vol.14 (4), p.1007-1019

2007

Volltextzugriff (PDF)

Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions

International journal of cancer, 2018-07, Vol.143 (2), p.383-395

2018

Volltextzugriff (PDF)

Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo

International journal of molecular sciences, 2013-06, Vol.14 (6), p.11942-11962

2013

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(79)

Sprache

Englisch
(79)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Interleukin-6 and prostate cancer: Current developments and unsolved questions

Interleukin-6: A multifunctional targetable cytokine in human prostate cancer

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer

Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205

Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer

New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium

Androgen Receptor–Interacting Proteins in Prostate Cancer Development and Therapy Resistance

Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer

Antidiabetic drugs influence molecular mechanisms in prostate cancer

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo

Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells

Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases

Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling

Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion

Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions

Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo

Suchergebnisse filtern